Reaching Others University at Buffalo - The State University of New York
Skip to Content
John                           Sullivan

John M. Sullivan MD, PhD

Department of Ophthalmology

Associate Professor of Ophthalmology

Specialty/Research Focus

Gene Expression; Gene therapy; Neurodegenerative disorders; Pathophysiology; Protein Folding; Retina; Signal Transduction

 
top-left cornertop-right corner
Professional Summary:

I am a Clinician Scientist working in the field of hereditary retinal and macular degenerations. I direct a regional referral service for these diseases at the Ross Eye Institute. My NIH- and VA-funded laboratory is focused on the development of gene-based therapeutics for hereditary retinal degenerations and common age-related macular degeneration.

Education and Training:
  • Fellowship, Retinal Degenerative Diseases, University of Michigan, Ann Arbor, MI, Clinical/Research Fellowship of Retinitis Pigmentosa Foundation (now Foundation Fighting Blindness) (1994)
  • Residency, Ophthalmology, Washington Univ. School Medicine, St. Louis MO (1992)
  • MD, Medicine/Biophysics, Mount Sinai School Medicine, NY (1987)
  • BA, Microbiology, Rutgers University, New Brunswick, NJ (1979)
Employment:
  • Associate Professor with tenure, University at Buffalo- State University of New York (2011-present)
  • Staff Physician, VA Western NY Healthcare System (2004-present)
  • Associate Professor- tenure track, University at Buffalo- State University of New York (2004–2011)
  • Assistant Professor, Upstate Medical University- State University of New York (1994–2004)
  • Lecturer in Ophthalmology, University of Michigan (1992–1994)
  • Fellow in Neurobiology; Staff Physician, Washington University School of Medicine; John Cochran Veterans Administration Hospital (1991–1992)
  • Resident in Ophthalmology (PGY2- PGY4), Washington University School of Medicine (1988–1991)
  • Intern (PGY1), St. John's Mercy Medical Center (1987–1988)

Grants and Sponsored Research:
  • September 2003–September 2007
    A Ribozyme Rescue Strategy for Autosomal Dominant Retinitis Pigmentosa
    National Eye Institute
    Role: Co-Investigator
    $975,000
  • June 1996–May 2001
    The Early Receptor Current of Rhodopsin Activation
    National Eye Institute
    Role: Co-Investigator
    $350,000

Journal Articles:
  • Brueggemann LI, Sullivan JM. HEK293S cells have functional retinoid processing machinery.. J Gen Physiol. 2002; 119(6).
  • Sullivan JM, Pietras KM, Shin BJ, Misasi JN. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.. Mol Vis. 2002; 8.
  • SULLIVAN J. Rhodopsin charge motions in the Schiff base counterion mutant E113Q. Invest. Ophthal. Vis. Sci. 2001; 42(S184).
  • SULLIVAN J Brueggemann L Anumonwo J. Voltage and proton sensitivity of rhodopsin activation. Biophys. J.. 2001; 80(19a).
  • SULLIVAN J L Chiu GM Seigel. Rhodopsin-induced apoptosis in a human cell culture system. Invest. Ophthal. Vis. Sci. 2000; 41(S404).
  • SULLIVAN J L Brueggemann P Shukla. An electrical approach to study rhodopsin activation in single cells with the early receptor current assay. Methods in Enzymology. 2000; 315.
  • Shukla P, Sullivan JM. Normal and mutant rhodopsin activation measured with the early receptor current in a unicellular expression system.. J Gen Physiol. 1999; 114(5).
  • Sullivan JM, Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system.. Biophys J. 1999; 77(3).
  • SULLIVAN J P Shukla. Time-resolved rhodopsin activation: early receptor current studies in a unicellular expression system.. Biophys. J. 1999; 76(148a).
  • SULLIVAN J Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system. Biophysical J. 1999; 77(3).
  • SULLIVAN J Shukla P. Normal and mutant rhodopsin activation measured with the early receptor current in a unicellular expression system.. J. General Physiology. 1999; 114.
  • SULLIVAN J. . Low-cost monochromatic microsecond flash microbeam apparatus for single-cell photolysis of rhodopsin or other photolabile pigments.. Rev. Sci. Inst. 1998.
  • SULLIVAN J Pietras KM Shin B. Design and testing of hammerhead ribozymes to cleave full-length opsin mRNA. Invest. Ophthal. Vis. Sci.. 1998; 39(S722).
  • SULLIVAN J Satchwell MF. Development of stable cell lines expressing mutant human rhodopsins. Invest. Ophthal. Vis. Sci. 1998; 39(S958).
  • SULLIVAN J Mason GO J Olik. A sutureless self-retaining infusion cannula for pars plana vitrectomy. Amer. J. Ophthalmol. 1990; 110.
  • SULLIVAN J Liebovitch LS. Fractal analysis of a voltage dependent potassium channel from cultured mouse hippocampal neurons. Biophysical J. 1987; 52.
See All (16 Total) >


Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

VA Western NY Healthcare System
Medical Research, Bldg 20, Rm 245
3495 Bailey Ave
Buffalo, NY 14215
Phone: (716) 862-6533
Fax: (716) 862-6526
Email: js354@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile